Healthcare

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.35-0.005 (1.409%)

(as on 2021-12-01 20:56:58 AEDT)

Market Cap : AUD 50.215 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.355 0.355 0.35 0.350L 0.355 H 0.200L 0.540 H
Last Trade 0.35
Change% -1.4085
52 W H/L 0.540/0.200
EBITDA -3.116 M
NPAT After Abnormal Items -3.178 M
Equity 14.604 M
ROE% -21.76%
Total Liabilities 223,412
Total Revenue 1.018 M
Cash and Cash Equivalents 14.162 M

Stock Information

Share price 0.35
Market Cap 50.215 M
Price/Gross Cash Flow -22.02
Dividend Yield Excluding Special 0.00%
Ending Shares 143.472 M
52-Week Range 0.540-0.200
P/E ratio 0.000
Sector P/E --
EPS -2.22
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.02
Net Gearing -96.97%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.10
Sales Per Share 0.00
Book Value Per Share 0.10

Announcements

Heading Date/Time
Adoption of New Constitution  11/11/2021 5:32PM
Results of Meeting  11/11/2021 4:59PM
Chairman's Address to Shareholders  11/11/2021 12:56PM
NSB Partners with Biospective for MS Studies  02/11/2021 8:39AM
Quarterly Activities/Appendix 4C Cash Flow Report  29/10/2021 6:38PM
Company Presentation - updated  26/10/2021 5:49PM
Company Presentation  26/10/2021 2:03PM
Completion of Safety Pharmacology Studies  18/10/2021 9:42AM
Proposed issue of securities - NSB  11/10/2021 2:53PM
Notice of Annual General Meeting/Proxy Form  11/10/2021 2:46PM
Appendix 4G  23/09/2021 4:45PM
Corporate Governance Statement  23/09/2021 4:45PM
Date of AGM & Closing Date for Director Nominations  21/09/2021 4:21PM
Broker Briefing Investor Webinar  08/09/2021 8:21AM
Company Presentation  03/09/2021 12:28PM
Investor Webinar  03/09/2021 12:27PM
NSB Receives R&D Advance & Overseas Finding  03/09/2021 9:05AM
Positive Results in Multiple Sclerosis Study  31/08/2021 8:05AM
2021 Annual Report and Appendix 4E  27/08/2021 1:33PM
NSB appoints International Scientific Advisors  24/08/2021 9:22AM
Results from Pulmonary Studies Clarification  20/08/2021 1:28PM
Trading Halt  19/08/2021 12:59PM
Pause in Trading  19/08/2021 12:13PM
Results from Pulmonary Studies  19/08/2021 8:11AM
Quarterly Update and Appendix 4C  30/07/2021 10:01AM
Change of Director's Interest Notice  13/07/2021 2:12PM
Successful completion of pivotal ocular safety study  01/07/2021 9:47AM
Trading Halt  30/06/2021 10:26AM
Pause in Trading  30/06/2021 10:04AM

Similar Companies

Related Articles

About Company

NSB is a drug development company engaged in developing peptide-based pharmaceutical drugs targeting neurodegenerative conditions with high unmet medical need at molecular level. Its portfolio of products incorporates multiple therapeutic products including a novel therapeutic peptide most advanced as a treatment for Alzheimer’s disease, EmtinB, plus other related peptides like EmtinAc, EmtinAn and EmtinBn with demonstrated similar therapeutic potential as EmtinB.

Corporate Information

company address Suite 5/85 Forrest Street, COTTESLOE, WA, AUSTRALIA, 6011

company phone08 6382 1800

company websitehttp://www.neuroscientific.com/

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/12/2017 -- 0.000 --

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-26 2022
Report (Prelim) 2022-08-26 2022
Report (Interim) 2022-02-22 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/12/2017
Trading Revenue -- -- -- --
Other Revenue 1.018 M 40,540 33,849 0
Total Revenue 1.018 M 40,540 33,849 0
Interest Income 27,645 35,733 85,437 0
Interest Expenses -63 -3,417 0 0
Expenses -4.162 M -2.885 M -1.723 M 0
EBITDA -3.144 M -2.844 M -1.689 M 0
Depreciation and Amortization -61,407 -56,661 -55,205 0
Depreciation -11,470 -6,741 -5,285 0
Amortisation -49,937 -49,920 -49,920 0
EBIT -3.205 M -2.901 M -1.744 M 0
Pre Tax Profit -3.178 M -2.869 M -1.659 M 0
Tax Expense 0 0 0 0
Net Profit After Tax -3.178 M -2.869 M -1.659 M 0
Minority Interest 0 0 0 0
Preference Dividend 0 0 0 0
Net Abnormal Items 0 0 0 0
Reported Net Profit After Abnormal Items -3.178 M -2.869 M -1.659 M 0
Ending Shares 143.472 M 78.385 M 73.581 M 52.325 M
Weighted Average Shares 143.472 M 78.385 M 71.527 M 52.325 M
EPS After Abnormal Items (cents) -2.22 -3.66 -2.32 0
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/12/2017
Total Current Assets 14.427 M 3.306 M 4.637 M 5.933 M
Total Non Current Assets 400,191 431,720 485,999 397,357
Total Assets 14.827 M 3.738 M 5.123 M 6.331 M
Total Current Liabilities 223,412 88,533 62,478 54,169
Total Non Current Liabilities 0 0 0 0
Total Liabilities 223,412 88,533 62,478 54,169
Net Assets 14.604 M 3.649 M 5.061 M 6.277 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/12/2017
Net Operating Cash -2.602 M -2.281 M -1.407 M 0
Net Invested Cash -29,878 -2,382 -19,079 0
Net Financing Cash Flows 13.507 M 960,798 5.932 M 0
Beginning Cash 3.287 M 4.61 M 103,895 0
End Cash Position 14.162 M 3.287 M 4.61 M 0
Exchange Rate Adjustments 0 0 0 0
Other Cash Adjustments 0 0 0 0
Ending Cash 14.162 M 3.287 M 4.61 M 0

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK